ALDH1A3 and type 2 diabetes mellitus: The findings that A+ β-cells can be converted to mature, functional β-cells by pair-feeding, and that genetic or pharmacologic inhibition of ALDH1A3 can improve β-cell dedifferentiation and dysfunction nominate ALDH1A3 as a potential therapeutic target in the treatment of T2D.